Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Markets ended higher on Monday, snapping a four-day losing streak. Nifty reclaimed 25,200, led by autos and pharma, while ...

India's equity benchmarks snapped a four-session losing streak on Tuesday, as lower-than-expected domestic inflation data boosted expectations of further rate cuts this year by the central bank. The ...

Indian benchmark indices concluded the trading session on a positive note, with the Sensex gaining over 300 points to end at 83,570. Nifty closed near the 25,200 mark at 25,195.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Indian equity indices, Sensex and Nifty, are expected to open on flat-to-higher note on Tuesday following positive global ...